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ABSTRACT
Nocardia infection is rare but potentially fatal. Therapy of Nocardia infection remains difficult. Lin-
ezolid, a novel oxazolidinone antibiotic, has proven to be effective, but clinical data are limited. Here 
we describe a case of a 45-year-old man with pulmonary N. farcinica infection following a liver 
transplantation. The initial therapy was trimethoprim-sulfamethoxazole, which showed no effect. 
According to susceptibility test, linezolid was administered with clearly improving the patient’s con-
dition. The treatment was stopped for anemia as drug related adverse event, and the therapy lasted 
for as long as 5 months. At the end of treatment clinical cure was confirmed and anemia reversed 
after discontinuation of linezolid. We also analyzed the clinical data of previously published reports 
by literature review, focusing on the efficacy and safety of linezolid treatment for Nocardia infection.
Keywords: Nocardia; linezolid; drug therapy; transplantation. 
months), recurrence of infection and drug in-
teractions are all major limitations.1,3 The best 
antibiotic therapy has not been well established. 
Conventional regimens include trimethoprim-
sulfamethoxazole (TMP-SMX), amikacin, 
imipenem, cephalosporin, minocycline and so 
on, but the prognosis remains depressing.1,3,4 
Linezolid has emerged as an attractive drug for 
Nocardia infection in recent years, but the ef-
ficacy, feasibility and safety of linezolid treat-
ment has not been well discussed.
Here we describe a patient with pulmonary 
Nocardia farcinica infection treated successful-
ly by linezolid following a liver transplantation. 
CASE REPORT
A 45-year-old man underwent living donor 
liver transplantation on June 11, 2009 for 
subacute liver failure due to hepatitis B. Sur-
gical technique and perioperative treatment 
were performed according to standard pro-
tocol. The early post-transplant course was 
unremarkable. Immunosuppressive agents 
consisted of tacrolimus (1 mg, q12h, orally), 
mycophenolate mofetil (500 mg, q12h, orally) 
and methylprednisolone [1,000 mg, intrave-
nously (IV), only used during operation]. The 
concentration of tacrolimus varied between 8 
and 10 ng/mL. Sulbactam/cefoperazone was 
administered for prophylaxis for a period of 
INTRODUCTION
Nocardia species are widespread ubiquitous 
saprophytes, showing positive and filamen-
tous bacilli in Gram staining.1 T lymphocyte-
mediated immune response plays a dominant 
role in preventing Nocardia infection.2 There-
fore, the most common underlying conditions 
happen in immunosuppressive hosts, and solid 
organ transplant recipients are predominant in 
the population susceptible to Nocardia infec-
tion.1,3,4 The reported prevalence of Nocardia 
infection in solid organ transplant recipients 
varies between 0.7-3.5%.3 Nocardia infection 
demonstrates a variety of clinical and radiolog-
ic manifestations. The microorganism mostly 
prefers to affect lung, ranging from granuloma-
tous to purulent, subacute to chronic infection, 
and other organs such as brain, skin, bone, kid-
ney and testis may be attacked as well.1,3-5
In spite of the low incidence, Nocardia in-
fection is potentially lethal, with high morbid-
ity and mortality. In some large scale studies, 
the mortality rate is about 14%, and for pa-
tients with central nervous system (CNS) in-
fection, it may be as high as 50%.1,3,4 Therapy 
is quite difficult. Drug resistance, drug related 
adverse events, absence of effective oral anti-
biotics for long-term therapy (pulmonary in-
fection should be treated for 6 months, and if 
CNS is involved, it must be prolonged for 9-12 
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two weeks. The allograft had played normal function one 
week after transplantation.
However, the patient developed an episode of acute 
rejection on the 10th postoperative day, which was con-
firmed by pathology. He was then treated with high dose 
IV steroids. At the same time, the dose of tacrolimus was 
increased to 15 ng/mL. His liver function gradually got 
better. On the 15th postoperative day, he started presenting 
fever as high as 38.5oC, and cough with little expectora-
tion. Physical examination was inconclusive. Laboratory 
investigation showed leucocytosis (15.4 x 109/L, of which 
89.8% granulocytes), and an elevated C-reactive protein 
(105 ng/mL). A computed tomography (CT) showed a 3-cm 
large nodule affecting the lower lobe of his left lung (Figure 
1A). The immunosuppression then tapered off and empiric 
antimicrobial therapy was administered (ceftriaxone and 
voriconazole), showing, however, no clinical improvement. 
The patient developed chest pain and mild dyspnea, in 
combination with more sputum. Culture of sputum did not 
provide useful information. In order to define the etiology, 
we performed a fine needle lung biopsy guided by CT on 
the 17th postoperative day. Five days later, culture of lung 
tissue turned out positive for Nocardia species (Figure 2) 
and the biopsy revealed abscess in pathology. Therefore, 
diagnosis of nocardial pneumonia was established. We 
performed magnetic resonance imaging (MRI) of the brain 
to exclude cerebral abscess. The initial therapy was oral 
TMP-SMX (TMP 160 mg and SMX 800 mg three times a 
day) for three days with no improvement. Then another 
CT showed the lesion had become larger with formation of 
abscess, infiltration and pleural effusion (Figure 1B). At the 
time, the bacilli were identified as N. farcinica, which was 
resistant to cotrimoxazole but sensitive to amikacin, lin-
ezolid and amoxicillin/clavulanic acid. The antibiotic treat-
ment was then set to linezolid (600 mg, twice a day, IV).
The patient’s clinical symptoms and laboratory data 
improved quickly after use of linezolid. Clear resolution 
of the lung infiltration and pleural effusion was obtained 
(Figure 1C). After 1 month of IV therapy, the regimen 
was replaced by oral linezolid (600 mg, twice a day) as 
follow-up therapy, and the patient was discharged. He 
was kept under regular follow-up since then. 
He remained asymptomatic except for a gradually aggra-
vated anemia (hemoglobin 79 g/L) during follow-up, which 
was considered as a drug related adverse event attributed to 
linezolid. To rule out other reasons for the anemia, linezol-
id treatment was stopped after five months. At the end of 
therapy, the lesion had been completely absorbed in the lung 
CT. He was confirmed to be clinically cured, and anemia 
recovered after discontinuation of linezolid. There was no 
evidence of clinical or radiological recurrence. The patient is 
alive with a well functioning allograft more than 16 months 
following his transplant.
Figure 1: CT demonstrates a 3-cm large nodule in the lower 
lobe of the left lung, at the time of symptoms onset (A). The 
lesion became larger with formation of abscess, infiltration 
and pleural effusion, after therapy of TMP-SMX (B). The lesion 
was smaller, with absorbed infiltration and pleural effusion 
after 2 weeks of linezolid treatment (C).
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Figure 2: In blood agar, typical colonies showed a chalky 
white, cotton candy appearance with reductus on the surface, 
which indicated Nocardia spp. growth.
DISCUSSION
Antibiotic therapy for Nocardia infection has been difficult 
for years. Based on the available literature, there are more 
than 50 species of Nocardia identified by phenotypic and 
molecular methods.1 The most frequently isolated species 
include N. asteroides, N. farcinica, N. nova and N. brasilien-
sis. Isolates of N. farcinica usually show high resistance to 
antibiotics and is associated with high mortality.1,3
TMP-SMX has functioned as first-line therapy for 
more than 60 years.1 But the mortality rate associated with 
TMP-SMX monotherapy is as high as 50%, especially in 
disseminated infection and CNS involvement, mostly due 
to drug resistance to some species such as N. farcinica.6 Al-
though amikacin and imipenem show good activity to most 
part of the isolated species, renal toxicity may be enhanced 
when simultaneous therapy of cyclosporine or tacrolimus is 
administered to transplant recipients.3 Research on alternative 
antibiotics such as cephalosporins and minocycline is scarce.
Linezolid, a novel oxazolidinone antibiotic, has gained 
more and more attention as primary therapy for Nocardia 
infection in recent years. In vitro investigations show con-
sistent sensitivity of all isolates of Nocardia species to lin-
ezolid, and, in vivo, the tissue penetration of linezolid is 
satisfactory, even in the cerebral spinal fluid.7,8 Furthermore, 
it is suitable for long-term therapy because it can be admin-
istered not only intravenously but also orally with 100% 
bioavailability.8 Linezolid has little renal or hepatic toxicity, 
and rarely has interactions with other drugs such as im-
munosuppressants, for it is not metabolized by human cy-
tochrome P450.2 
Through literature review, we identified 14 addition-
al cases of linezolid monotherapy or combined therapy 
for Nocardia infection published in English literature, 
and detailed clinical data about these reports are shown 
in Table 1. 
The earliest report was from 2003. Six of these cases were 
reported in an original article.9 Two of them were associated 
with liver transplantation.5 Most of the strains isolated were 
N. farcinica (6 cases) and N. asteroides (6 cases). In more 
than half of the patients (8 cases) CNS was involved. The du-
ration of linezolid therapy could be as long as 24.5 months.9 
In most cases linezolid was not initially prescribed. It was 
only used as salvage therapy when previous therapy failed. 
Sometimes it was administered in combination with other 
regimens, such as TMP-SMX, amikacin, meropenem and 
minocycline. The outcome of linezolid therapy was quite 
good, with 13 cases confirmed to have reached clinical cure. 
Drug related adverse events were not rare, especially in pro-
longed usage for several months. Adverse events attributed 
to linezolid were observed in 10 cases. The most common 
severe side-effects were myelosuppression (7 cases), lactic 
acidosis (2 cases), peripheral neuropathy (3 cases) and optic 
neuropathy (1 case). Myelosuppression often induced ane-
mia and thrombocytopenia. As a result, drug toxicity was 
the most significant reason for discontinuation of linezolid 
treatment, which led to discontinuation of therapy in 8 cases. 
In the present case, considering that empiric treatment 
with TMP-SMX did not show effectiveness and accord-
ing to the species identification and susceptibility test, we 
chose linezolid as primary antibiotic regimen. Linezolid 
showed excellent efficacy with clear improvement of clini-
cal and radiologic manifestations. There was no evidence 
for interaction with immunosuppressant, but anemia was 
observed and was confirmed to be linezolid-related, which 
eventually resulted in treatment discontinuation. Therapy 
lasted for five months and no recurrence occurred during 
follow-up. Monotherapy of linezolid may avoid the need to 
use multiple treatments such as amikacin and imipenem, 
whose renal toxicity may be enhanced by the use of tacroli-
mus; they are also unsuitable for long-term therapy as they 
are not available orally. The good prognosis of this case 
may be attributed to the early effective therapy of linezolid 
and no organ involved other than lung. 
In conclusion, linezolid shows superior effectiveness to 
treat Nocardia infection in relation to traditional antibiot-
ics such as TMP-SMX. It has significant activity against all 
species including N. farcinica and appears to be a potential 
reasonable agent to treat Nocardia infection. But the safe-
ty of prolonged use of linezolid should be a concern and 
its value as first or second-line therapy, initial or salvage 
therapy for Nocardia infection warrants more clinical data.
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Table 1. Published reports of Nocardia infection treated with linezolid
Case reports Involved Nocardia spp. Linezolid Adverse events Stopped for Outcome 
(number of organs  therapy  due to 
patients)   period   adverse events  
 Skin (3),   
12 m,
     
 CNS (2),   
3 m, 
    
Moylett 
lung (4),  N. asteroides (3),  
2 m,
 Myelosuppression (3),  Cure (5),  
et al.9 (6)
 liver (1),  N. brasiliensis (1), 
4 m,  
lactic acidosis (1), Yes (2) suspected 
 kidney (1),  N. otitidiscaviarum (2) 
24.5 m,  
peripheral neuropathy (1)  recurrence (1) 
 adrenal   
12 m
 
 glands (1), 
 Lung,      
Lewis skin,  
N. farcinica
 
4 m
 Myelosuppression,  
Yes Cure
 
et al.10 (1) kidney,    visual impairment 
 CNS
Moitra 
Lung, CNS N. asteroides 4 m Peripheral neuropathy Yes Cure
 
et al.11 (1)
Rupprecht CNS N. farcinica 1.6 m None No Cure 
et al.12 (1)
Viganò Lung, CNS N. farcinica 2 m Anemia Yes Cure 
et al.13 (1)
Justiniano 
CNS N. asteroides NR None No  Improvement 
 
et al.14 (1)
Rivero Pleura,  
N. farcinica 17 m Peripheral neuropathy No Cure
 
et al.15 (1) pericardium
del Pozo Soft tissue, 
N. asteroides 1 m Lactic acidosis Yes Cure
 
et al.5 (1) bone, CNS
Gowrinath 
Lung N. farcinica	 0.5	m	 Myelosuppression	 Yes	 Cure
 
et al.16 (1)
This report (1) Lung N. farcinica 5 m Anemia Yes Cure
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